Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Hooks, G. Jones, A. Smith, D. Neill, J. Justice (1991)
Individual differences in locomotor activity and sensitizationPharmacology Biochemistry and Behavior, 38
K. Gysling, Rex Wang (1983)
Morphine-induced activation of A10 dopamine neurons in the ratBrain Research, 277
Kretschmer Kretschmer, Zadow Zadow, Volz Volz, Volz Volz, Schmidt Schmidt (1992)
The contribution of different binding sites of the N‐methyl‐D‐aspartate (NMDA) receptor to the expression of behaviorJ. Neural Transm., 87
H. Bergman, T. Wichmann, M. DeLong (1990)
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.Science, 249 4975
M. Hiramatsu, A. Cho, Nabeshima Toshitaka (1989)
Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine.European journal of pharmacology, 166 3
B. Clineschmidt, G. Martin, P. Bunting, N. Papp
Central sympathomimetic activity of (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo [a, d]cyclohepten‐5,10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic propertiesDrug Development Research, 2
Roberts Roberts, Corcoran Corcoran, Fibiger Fibiger (1977)
On the role of ascending catecholaminergic systems in intravenous self‐administrationPharmacol. Biochem. Behav., 6
M. Babbini, W. Davis (1972)
Time‐dose relationships for locomotor activity effects of morphine after acute or repeated treatmentBritish Journal of Pharmacology, 46
M. Wolf, M. Khansa (1991)
Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamineBrain Research, 562
R. Karler, L. Calder, I. Chaudhry, S. Turkanis (1989)
Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801.Life sciences, 45 7
R. Boldry, N. Uretsky (1988)
The importance of dopaminergic neurotransmission in the hypermotility response produced by the administration of N-methyl-d -aspartic acid into the nucleus accumbensNeuropharmacology, 27
J. Lehmann, A. Hutchison, S. McPherson, C. Mondadori, M. Schmutz, C. Sinton, C. Tsai, D. Murphy, D. Steel, M. Williams (1988)
CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist.The Journal of pharmacology and experimental therapeutics, 246 1
A. Imperato, M. Scrocco, S. Bacchi, L. Angelucci (1990)
NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus.European journal of pharmacology, 187 3
R. Wise, M. Bozarth (1987)
A psychomotor stimulant theory of addiction.Psychological review, 94 4
R. Cadena, Robert Colman (1991)
Structure and functions of human kininogens.Trends in pharmacological sciences, 12 7
Tiedtke Tiedtke, Bischoff Bischoff, Schmidt Schmidt (1990)
MK‐801‐induced stereotypy and its antagonism by neuroleptic drugsJ. Neural Transm., 81
Liljequist Liljequist (1991)
Genetic differences in the effects of competitive and non‐competitive NMDA receptor antagonists on locomotor activity in micePsychopharmacology, 104
M. Bozarth, R. Wise (1984)
Anatomically distinct opiate receptor fields mediate reward and physical dependence.Science, 224 4648
French French, Ceci Ceci (1990)
Non‐competitive N‐methyl‐D‐aspartate antagonists are potent activators of ventral tegmental A10 dopamine neuronsNeurosci. Lett., 119
H. Ujike, H. Tsuchida, A. Kanzaki, K. Akiyama, S. Otsuki (1992)
Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization.Life sciences, 50 22
M. Wolf, M. Jeziorski (1993)
Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitizationBrain Research, 613
Marie-Odile Krebs, J. Desce, M. Kemel, C. Gauchy, G. Godeheu, A. Chéramy, Jacques Glowinski (1991)
Glutamatergic Control of Dopamine Release in the Rat Striatum: Evidence for Presynaptic N‐Methyl‐D‐Aspartate Receptors on Dopaminergic Nerve TerminalsJournal of Neurochemistry, 56
P. Elliott, S. Close, D. Walsh, A. Hayes, A. Marriott (1990)
Neuroleptic-induced catalepsy as a model of Parkinson's disease II. Effect of glutamate antagonistsJournal of Neural Transmission - Parkinson's Disease and Dementia Section, 2
M. Bubser, U. Keseberg, P. Notz, W. Schmidt (1992)
Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats.European journal of pharmacology, 229 1
J. Deminière, P. Piazza, M. Moal, Hervé Simon (1989)
Experimental approach to individual vulnerability to psychostimulant addictionNeuroscience & Biobehavioral Reviews, 13
Carlsson Carlsson, Carlsson Carlsson (1989a)
The NMDA antagonist MK‐801 causes marked locomotor stimulation in monoamine‐depleted mice.J. Neural Transm., 75
E. French, A. Ceci (1990)
Non-competitive N-methyl-d-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neuronsNeuroscience Letters, 119
W. Koek, J. Woods, G. Winger (1988)
MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys.The Journal of pharmacology and experimental therapeutics, 245 3
L. Dumars, Lynn Rodger, P. Kalivas (1988)
Behavioral cross-sensitization between cocaine and enkephalin in the A10 dopamine regionBehavioural Brain Research, 27
M. Wolf, F. White, X.-T. Hu (1993)
Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system.Behavioural pharmacology, 4 4
E. Joyce, S. Iversen (1979)
The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the ratNeuroscience Letters, 14
K. Trujillo, H. Akil (1991)
The NMDA receptor antagonist MK-801 increases morphine catalepsy and lethalityPharmacology Biochemistry and Behavior, 38
R. Wise (1987)
The role of reward pathways in the development of drug dependence.Pharmacology & therapeutics, 35 1-2
J. Stewart, P. Vezina (1987)
Environment-specific enhancement of the hyperactivity induced by systemic or intra-VTA morphine injections in rats preexposed to amphetaminePsychobiology
T. Robinson, J. Becker (1986)
Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosisBrain Research Reviews, 11
D. Corbett (1989)
Possible abuse potential of the NMDA antagonist MK-801Behavioural Brain Research, 34
G. Koob, F. Bloom (1988)
Cellular and molecular mechanisms of drug dependence.Science, 242 4879
W. Schmidt, M. Bubser (1989)
Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in ratsPharmacology Biochemistry and Behavior, 32
P. Kalivas, B. Weber (1988)
Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine.The Journal of pharmacology and experimental therapeutics, 245 3
R. Karler, I. Chaudhry, L. Calder, S. Turkanis (1990)
Amphetamine behavioral sensitization and the excitatory amino acidsBrain Research, 537
P. Vezina, J. Stewart (1984)
Conditioning and place-specific sensitization of increases in activity induced by morphine in the VTAPharmacology Biochemistry and Behavior, 20
P. Kalivas, S. Taylor, J. Miller (1985)
Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. I. Behavioral characterization.The Journal of pharmacology and experimental therapeutics, 235 2
P. Marek, S. Ben-Eliyahu, M. Gold, J. Liebeskind (1991)
Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the ratBrain Research, 547
M. Thiébot, J. Kloczko, R. Chermat, P. Soubrié, A. Puech, P. Simon (1982)
A simple model for studying benzodiazepines: Potentiation of hyperactivity induced by cocaine in miceDrug Development Research, 2
R. Karler, L. Calder, S. Turkanis (1991)
DNQX blockade of amphetamine behavioral sensitizationBrain Research, 552
T. Aziz, D. Peggs, M. Sambrook, A. Crossman (1991)
Lesion of the subthalamic nucleus for the alleviation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in the primateMovement Disorders, 6
M. Carlsson, A. Carlsson (1990)
Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's diseaseTrends in Neurosciences, 13
M. Bozarth, R. Wise (1981)
Intracranial self-administration of morphine into the ventral tegmental area in rats.Life sciences, 28 5
Boldry Boldry, Uretsky Uretsky (1988)
The importance of dopaminergic neurotransmission in the hypermotility response produced by the administration of N‐methyl‐D‐aspartic acid into the nucleus accumbensNeuropharmacology, 27
K. Trujillo, H. Akil (1991)
Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.Science, 251 4989
2-deoxyglucose in monkeys exposed to l-methyl-4-phenyl-l,2,3,6-tet-rahydropyridine (MPTP)
W. Schmidt, D. Bury (1988)
Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum of the rat.Life sciences, 43 6
D. Roberts, M. Corcoran, H. Fibiger (1977)
On the role of ascending catecholaminergic systems in intravenous self-administration of cocainePharmacology Biochemistry and Behavior, 6
D. Roberts, G. Koob (1982)
Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in ratsPharmacology Biochemistry and Behavior, 17
Stewart Stewart, Druhan Druhan (1993)
Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non‐competitive NMDA receptor antagonist, MK‐801Psychopharmacology, 110
M. Vasko, E. Domino (1978)
Tolerance development to the biphasic effects of morphine on locomotor activity and brain acetylcholine in the rat.The Journal of pharmacology and experimental therapeutics, 207 3
Carlsson Carlsson, Carlsson Carlsson (1989b)
Interactions between glutamatergic and monoaminergic systems within the basal ganglia–implications for schizophrenia and Parkinson's disease.Trends Pharmacol. Sci., 12
T. Klockgether, L. Turski (1990)
NMDA antagonists potentiate antiparkinsonian actions of L‐dopa in monoamine‐depleted ratsAnnals of Neurology, 28
G. Collingridge, W. Singer (1990)
Excitatory amino acid receptors and synaptic plasticity.Trends in pharmacological sciences, 11 7
I. Mitchell, C. Clarke, S. Boyce, R. Robertson, D. Peggs, M. Sambrook, A. Crossman (1989)
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineNeuroscience, 32
U. Wüllner, A. Kupsch, G. Arnold, P. Renner, C. Scheid, R. Scheid, W. Oertel, T. Klockgether (1992)
The competitive NMDA antagonist CGP40.116 enhances L-DOPA response in MPTP-treated marmosetsNeuropharmacology, 31
R. Matthews, D. German (1984)
Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphineNeuroscience, 11
W. Löscher, D. Hönack (1992)
The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems.European journal of pharmacology, 215 2-3
P. Kalivas, J. Stewart (1991)
Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activityBrain Research Reviews, 16
J. Brotchie, I. Mitchell, M. Sambrook, A. Crossman (1991)
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primateMovement Disorders, 6
Acute administration of morphine (10 mg/kg) to rats elicited an increase in locomotion that became sensitized upon repeated treatment over 14 days. Administration of the noncompetitive N‐methyl‐D‐aspartate receptor (NMDA) antagonist MK‐801 (0.1 or 0.25 mg/kg) prior to each morphine injection prevented the development of behavioral sensitization to morphine, an effect that persisted even after a 7‐day withdrawal from repeated treatment. Sensitization was also prevented by coadministration of the competitive NMDA receptor antagonist CGS 19755 (10 mg/kg). In contrast, acute pretreatment with MK‐801 did not alter the response of sensitized rats to morphine challenge, indicating that MK‐801 does not prevent the expression of sensitization. When administered alone, MK‐801 produced stereotyped movements at moderate doses (0.25 rng/kg) and horizontal locomotion at higher‐ doses, (0.5 mg/kg). Repeated administration of 0.25 mg/kg MK‐801 elicited sensitization to its own locomotor stimulatory effects, such that this dose became capable of eliciting horizontal locomotion. Sensitization was not seen during repeated administration of 0.1 mg/kg MK‐801 or 10 mg/kg CGS 19755, although both of these pretreatments did produce a sensitized response to subsequent challenge with 0.25 mg/kg MK‐801. This effect was enhanced by coadministration of morphine, even though repeated administration of morphine alone failed to sensitize rats to MK‐801 challenge. These results suggest a complex interplay between NMDA and opioid receptors, such that NMDA antagonists prevent morphine sensitization while morphine enhances the ability of NMDA antagonists to elicit sensitization to their own locomotor stimulatory effects. © 1994 Wiley‐Liss, Inc.
Synapse – Wiley
Published: Feb 1, 1994
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.